PMID- 15580397
OWN - NLM
STAT- MEDLINE
DCOM- 20050225
LR  - 20131121
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 39
IP  - 11
DP  - 2004 Nov
TI  - Second-line treatment for Helicobacter pylori infection in Japan: proton pump 
      inhibitor-based amoxicillin and metronidazole regimen.
PG  - 1051-5
AB  - BACKGROUND: Recent studies have reported that proton pump inhibitor 
      (PPI)/amoxicillin (A) metronidazole (M) therapy for Helicobacter pylori infection 
      provides a sufficient cure rate in Japan in patients who have failed first-line 
      treatment with PPI/amoxicillin and clarithromycin (AC). To validate the efficacy 
      of this regimen as second-line therapy, our experience with second-line treatment 
      using a PPI/AM regimen was reviewed. METHODS: We analyzed data on 151 patients 
      who had been prescribed a 10-day PPI/AM re-treatment regimen after eradication 
      failure of 1 to 2 weeks' first-line PPI/AC therapy. The PPI/AM regimen was given 
      according to results of susceptibility testing (S+) in 31 patients. The group 
      that had undergone susceptibility testing was further divided into two subgroups 
      according to dosage: standard dose of omeprazole (O)/AM (n = 11) and double dose 
      of lansoprazole (L)/AM (n = 20). The PPI/AM regimen was given without 
      susceptibility testing (S-) to 120 patients. These patients were also divided 
      into two subgroups according to whether they received omeprazole or lansoprazole: 
      OAM (n = 61) and LAM (n = 59). Cure rates and adverse effects in each group were 
      analyzed. RESULTS: The intention-to-treat (ITT)-based cure rate with/without 
      susceptibility testing was 93.5% (95% confidence interval [CI], 79%-99%) and 
      87.5% (95% CI, 80%-93%), respectively (not significant [NS]). The ITT-based cure 
      rate in S+/S- for OAM and S+/S- for LAM was 90.9% (95% CI, 59%-100%)/82% (95% CI, 
      70%-91%), and 95% (95% CI, 75%-100%)/93.2% (95% CI, 84%-98%), respectively (NS). 
      Adverse effects were seen in 26.3% and 32.5% of patients in the OAM group and the 
      LAM group, respectively (NS). CONCLUSIONS: The 10-day PPI/AM re-treatment regimen 
      is safe and effective, suggesting its usefulness as second-line treatment in 
      Japan in patients who have failed initial treatment with the PPI/AC regimen.
FAU - Nagahara, Akihito
AU  - Nagahara A
AD  - Department of Internal Medicine, Juntendo Koshigaya Hospital, Saitama, Japan.
FAU - Miwa, Hiroto
AU  - Miwa H
FAU - Kawabe, Masato
AU  - Kawabe M
FAU - Kurosawa, Akihiko
AU  - Kurosawa A
FAU - Asaoka, Daisuke
AU  - Asaoka D
FAU - Hojo, Mariko
AU  - Hojo M
FAU - Iijima, Katsuyori
AU  - Iijima K
FAU - Terai, Takeshi
AU  - Terai T
FAU - Ohkusa, Toshifumi
AU  - Ohkusa T
FAU - Miyazaki, Akihisa
AU  - Miyazaki A
FAU - Sato, Nobuhiro
AU  - Sato N
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Amoxicillin/administration & dosage/*therapeutic use
MH  - Anti-Infective Agents/administration & dosage/therapeutic use
MH  - Anti-Ulcer Agents/administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Metronidazole/administration & dosage/*therapeutic use
MH  - Middle Aged
MH  - Omeprazole/administration & dosage/*analogs & derivatives/therapeutic use
MH  - *Proton Pump Inhibitors
MH  - Retreatment
MH  - Time Factors
EDAT- 2004/12/08 09:00
MHDA- 2005/02/26 09:00
CRDT- 2004/12/08 09:00
PHST- 2003/12/16 00:00 [received]
PHST- 2004/03/31 00:00 [accepted]
PHST- 2004/12/08 09:00 [pubmed]
PHST- 2005/02/26 09:00 [medline]
PHST- 2004/12/08 09:00 [entrez]
AID - 10.1007/s00535-004-1443-5 [doi]
PST - ppublish
SO  - J Gastroenterol. 2004 Nov;39(11):1051-5. doi: 10.1007/s00535-004-1443-5.